Abstract
Introduction
Aplidin s is an antitumor compound in Phase II clinical trials against a variety of tumors. Chemically, it is a cyclic depsipeptide originally isolated from the marine tunicate Aplidium albicans and currently obtained by total synthesis. 1 
Aplidin
s is an extremely potent inducer of apoptosis, with IC 50 in the low nanomolar range, of many tumor cell types in vitro, [2] [3] [4] and it also exhibits strong antitumor activity in xenograft models. 5 The mechanism of action of Aplidin s is only partially understood. It induces apoptosis via caspase-dependent and -independent mechanisms irrespective of the p53 tumor suppressor status and without affecting the cell cycle phases. 4, [6] [7] [8] In human breast MDA-MB-231, cervical HeLa and several renal cancer cells Aplidin s causes a rapid and sustained increase in the phosphorylation of epidermal growth factor receptor (EGFR) and the activation of the kinases Src, Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK). 4, 9 These effects are attenuated by addition of exogenous reduced glutathione (L-g-glutamyl-Lcysteinylglycine, GSH) or Ebselen or N-acetylcysteine, both of which raise the cellular content of GSH. In HeLa cells, Aplidin s also induces extracellular signal-regulated kinase (ERK) and protein kinase C-d, and rapidly induces the apoptotic mitochondrial pathway thus promoting cytochrome c release from the mitochondria and caspase-3 activation. 9 By using a series of inhibitors and several genetically deficient mouse embryo fibroblasts (MEF) we showed that JNK activation precedes that of EGFR and is critical for apoptosis induction by Aplidin s . 10 Data indicated that the phosphorylation by JNK of c-Jun and other unknown substrates is crucial for Aplidin s cytotoxicity. 10 Aplidin s rapidly induces a series of genes of the JUN and FOS families, and p65/RELA in MDA-MB-231 cells, which leads to a transient increase in activator protein (AP)-1 and nuclear factor kappa B (NFkB) activity.
The action of Aplidin s in human hematopoietic cells such as T-lymphoid Jurkat, promyelocytic HL-60 and erythroleukemic HEL cell lines has also been studied. In these cells, Aplidin s also activates JNK, and promotes both the mitochondrial and the Fas/CD95 receptor apoptotic pathways. 11 In leukemic MOLT-4 cells, Aplidin s inhibits growth and induces apoptosis through the blockade of the vascular endothelial growth factor (VEGF)/VEGF receptor-1 autocrine loop via the inhibition of VEGF secretion. 12 In line with this, Aplidin s is anti-angiogenic by inhibiting VEGF-and fibroblast growth factor-2-induced endothelial cell functions (proliferation, migration, invasiveness). 13 However, Aplidin s inhibited VEGF secretion only in one out of four lines derived from patients with acute lymphoblastic leukaemia, and this effect was unrelated to its cytotoxicity. 14 In conditions of maximal growth stimulation in vitro no differences in drug sensitivity have been observed between normal and tumoral cells. However, non-tumoral human cells were more sensitive to Aplidin s upon growth-stimulation than in serum-starvation. This difference, which is not seen in tumoral cells probably because of their autocrine stimulation, is reflected in higher activation of JNK. 10 Here we examine the molecular mechanism of induction of apoptosis by Aplidin s in MDA-MB-231 cells focusing on two aspects: the importance of GSH and the mechanism of JNK activation. First, we show that Aplidin s alters cellular glutathione homeostasis thus increasing the ratio of oxidized (GSSG) to reduced (GSH) forms (GSSG/GSH) by altering several mechanisms of glutathione control. Our data indicate that this effect is essential for the induction of apoptosis, and leads to increases in levels of reactive oxygen species (ROS) and lipid and DNA oxidation. Second, we report that Aplidin s induces rapid, transient and GSH-dependent stimulation of the Rac1 small GTPase, upstream activator of JNK in several cell types. Rac1 activation plays an important role in JNK activation as both Rac1 downregulation by transfection of siRNA duplexes specific for Rac1 and the co-treatment with a specific inhibitor of Rac1 activity consistently diminished JNK activation and apoptosis induction by the drug. Moreover, Aplidin s decreases the cellular level of MKP-1, a major phosphatase inactivating JNK, with kinetics compatible with the sustained activation of JNK observed in drug-treated cells.
Results

GSH is crucial for Aplidin s cytotoxicity
First, we studied the effects of a series of antioxidants on the induction by Aplidin s of EGFR and JNK/p38MAPK phosphorylation and apoptosis. Only Ebselen and NAC, which increase cellular GSH levels, inhibited EGFR and JNK/p38MAPK activation (Table 1) . Aplidin s -induced apoptosis was also inhibited by Ebselen, and to a lesser extent by thiourea, whereas longer treatments with NAC were cytotoxic. In contrast, BSO, an inhibitor of the g-glutamylcysteine synthetase required for GSH synthesis, increased Aplidin s -induced kinase activities and apoptosis. These results pointed to GSH as a crucial mediator of Aplidin s action. Moreover, exogenous GSH prevented the loss of mitochondrial membrane potential (DCm) caused by Aplidin s as estimated by flow cytometry using JC-1: the drug caused an increase in the green and a decrease in the red fluorescence that was blunted by GSH ( Figure 1a) . Furthermore, exogenous GSH also reduced cell death caused by the drug (Figure 1b ). MDA-MB-231 cells were incubated overnight with the indicated antioxidants before addition of Aplidin (500 nM). EGFR activation was analyzed by coupled immunoprecipitation and Western blotting using antl-EGFR and anti-phosphotyrosine antibodies, respectively. JNK and p38 MAPK activation was analyzed by Western blotting using anti-phospho-JNK and anti-phospho-p38 MAPK antibodies. Anti-total JNK and p33 MAPK antibodies were used for normalization. Increase and Decrease mean 50% elevation or reduction as compared to cells incubated with vehicle before addition of Aplidin in at least three independent experiments. No means that change caused by pretreatment with the antioxidant was less than 50%. Apoptosis induction was analyzed by flow cytometry 24 h after Aplidin addition. G1 arrest or Cytotoxic mean that the antioxidant itself induced substantial (430%) accumulation of cells in G1 phase or the hypodiploid subG1 peak, respectively. Decrease means that pretreatment with the antioxidant diminished 430% the hypodiploid peak induced by Aplidin. No means that the effect was smaller than 30%.
Three independent experiments were done in every case Aplidin s modulates GSH content, Rac1 and MKP-1 L González-Santiago et al Aplidin s increases the GSSG/GSH ratio and induces oxidative stress Next, we examined the effect of Aplidin s on cellular glutathione homeostasis, by measuring the levels of GSH and GSSG in MDA-MB-231 cells. Aplidin s induced a decrease in GSH and an increase in GSSG levels, thus raising the GSSG/GSH ratio (Figure 2a ). This effect was blocked by Ebselen. Given the crucial role of glutathione in the control of the cellular redox status, the increase in GSSG/ GSH ratio suggested the generation of oxidative stress. Indeed, we found a progressive increase by Aplidin s of the cellular content of malondialdehyde, a marker of membrane phospholipid oxidation, which was prevented by BHA, an inhibitor of lipoperoxidation (Figure 2b) . Likewise, Aplidin s increased the level of 8-oxo-2 0 -deoxyguanosine, a marker of DNA oxidation (Figure 2c ). Further supporting the induction of oxidative stress, overexpression of exogenous thioredoxin, the second major cellular antioxidant system together with GSH, decreased the level of JNK activation by Aplidin s (Figure 2d) . Moreover, by incubating the cells in phosphatebuffered saline (PBS) we found that Aplidin s induced the extrusion of GSH to the extracellular medium ( Table 2) . To study the effect of GSH extrusion, we examined the effect of inhibitors of plasma membrane GSH transport: L-methionine and L-cystathionine, of the sinusoidal system, and BSP, of the canalicular system. All three compounds decreased JNK activation and cell death by Aplidin s (Figure 3 ). We also studied the effect of Aplidin s on the enzymes responsible for GSSG-GSH interconversion. Aplidin s induced a rapid, strong but transient inhibition of GPx activity, and a later decrease in GR, which may contribute to the disruption of glutathione homeostasis ( Figure 4 ). In line with these data, Aplidin s increased the cellular levels of ROS as measured by flow cytometry using 2 0 ,7 0 -DCFH-DA, an effect that was largely prevented by exogenous GSH treatment (Figure 5a ).
Early GSH depletion and loss of mitochondrial function are associated with later changes in ROS generation and disruption of Ca 2 þ homeostasis in some apoptotic systems. 15 We studied the effect of Aplidin s on intracellular Ca 2 þ levels in two conditions. First, we found a rapid transient decrease in intracellular Ca 2 þ when cells were labeled with Fluo-4 and treated with Aplidin s in normal Ca 2 þ -containing growth medium (Figure 5b , left part). Ca 2 þ levels progressively normalized and reached higher levels at 1 h post-treatment concomitantly with an increase in cell membrane permeability revealed by a decrease in FDA fluorescence, suggesting that the recovery may be attributable to Ca 2 þ influx from the extracellular medium. At this early time, no incorporation of PI was detected. Second, when cells were treated with Aplidin s in normal growth medium, washed and then labeled in Ca 2 þ -free medium intracellular Ca 2 þ levels decreased and did not recover for 10 h (Figure 5b , right part). These data do not support a major role of Ca 2 þ in Aplidin s action. We also examined whether Cu 2 þ , a pro-oxidant agent that mediates neuronal cell death induced by GSH depletion in neurons, 16 treatment (500 nM) initiated 24 h after transfection were measured by Western blot using phospho-specific antibodies (P-JNK). An antibody against total JNK protein was used to rule out effects at the expression level. Numbers refer to fold-increase activation with respect to untreated (À) cells (Table 3 ). The possibility that GSH could interact directly with the drug and block its cytotoxic activity was ruled out in experiments in which GSH and Aplidin s were pre-incubated together before addition to MDA-MB-231 cells. In such conditions we found the same level of inhibition of JNK activation and cell death as when cells were pretreated with GSH for 30 min and then with the drug (data not shown).
As GSH depletion induces cell death via activation of phospholipase A2 (PLA2) and lipoxygenases (LPO) in some neuronal populations, 17 and also activates a 12-LPO in epithelial cells, 18 we explored the effect of the inhibition of these enzymes on Aplidin s action. However, neither ATK (arachidonyl-L-trifluoromethylketone), a PLA2 inhibitor, nor baicalein (12-LPO inhibitor), 5,6-dehydro-arachidonic acid (15-LPO inhibitor) nor 12-nordihydroguaiaretic acid (a general LPO inhibitor) significantly affected Aplidin s -induced Jun N-terminal kinase activation or apoptosis (data not shown). Likewise, RHC-80267/U-57908, an inhibitor of diacylglycerol kinase, which is another source of arachidonic acid in addition to PLA2, also failed to modulate Aplidin s action. These results indicate that neither PLA2 nor LPO plays a major role in Aplidin s action. Next, we examined whether Aplidin s affected the interaction between JNK and glutathione S-transferases (GST)-p1p2. These proteins bind JNK and inhibit its activity acting as monomers in normal cell conditions and are released from JNK to form dimers under oxidative stress conditions. 19 As expected, the induction of JNK phosphorylation and cell death by Aplidin s was higher in cells deficient for GST-p1/p2 than in wild-type MEF. In line with this, Aplidin s promoted the rapid and transient formation of dimers in wild-type fibroblasts (not shown). However, by coupled immunoprecipitation and Western blotting we found that Aplidin s did not affect the interaction of JNK with glutathione-S-transferase (GST)-p1/ p2 in MDA-MB-231 cells (not shown), which indicates that these enzymes do not mediate Aplidin s action.
Aplidin s activates the Rac1 small GTPase and downregulates MKP-1 phosphatase JNK is activated by oxidative stress and other stimuli in various cell types through mechanisms that are not fully understood. [20] [21] [22] [23] We examined whether the activation of JNK by Aplidin s was a direct effect on the enzyme or the indirect result of the modulation of upstream regulator(s). We studied the activity of Ras, Rho and Rac1 small GTPases, which activate JNK in many biological systems. [24] [25] [26] We found that the drug consistently induces a rapid increase in the Rac1, but not Ras or Rho, activity in HeLa cells (Figure 6a , and data not shown). The cellular content of Rac1 was unchanged. The activation of Rac1 by Aplidin is not specific to HeLa cells, as it was also found in human MDA-MB-231 breast and LS174-T colon cells and in MEF (Figure 6b ). Moreover, Rac1 activation by the drug was also found in JNK-deficient (jnk1/2 À/À ) MEF, (Table 4) . Transfection of b-actin siRNA had no effect (not shown).
To further examine the role of Rac1 activation in Aplidin s action, we used a specific Rac1 inhibitor that has been recently become available (see Materials and Methods). This compound prevented in a dose-dependent manner both the cytotoxicity and the activation of JNK by Aplidin s in MDA-MB-231 ( Figure 8a ) and HeLa (Figure 8b ) cells. Together with the siRNA data, these results show the importance of Rac1 activation for Aplidin s action. In addition, we studied MKP-1, a dual phosphatase that dephosphorylates and deactivates members of the MAPK family (JNK and p38 with preference over ERK), and is regulated by multiple pathways and agents. 27 By Western blotting we found that Aplidin s decreased the levels of MKP-1 (Figure 9c) . In contrast to Rac1 activation, exogenous GSH did not prevent the reduction of MKP-1 levels (data not shown). MKP-1 downregulation does not reflect an unspecific effect on cellular phosphatases, as Aplidin streated cells showed no changes in the total cellular phosphatase activity, as measured by the p-nitrophenyl phosphate method (data not shown), although effects on phosphatases other than MKP-1 cannot be ruled out. The À/À showed slightly higher sensitivity to MEF wild-type, particularly at low drug concentrations (Figure 9d ). This is consistent with the higher level of JNK activation induced by the drug in MEF mkp-1 À/À cells ( Figure 9e) .
As the effects of Aplidin s on Rac1 and MKP-1 are rapid and post-transcriptional, we assessed whether gene expression is required for its cytotoxicity. To this end, MDA-MB-231 and MCF-7 cells were pre-incubated for 30 min with actinomycin D (transcription inhibitor) or cycloheximide (translation inhibitor) and then with Aplidin s for 4 or 7 h. The culture medium was then changed and cells were extensively washed and incubated in fresh medium. No differences in cell viability 48 h after drug addition were found in the presence or absence of the inhibitors, indicating that Aplidin s cytotoxicity does not require gene expression de novo (data not shown) in spite of the fact that p65/RELA and several genes of the JUN and FOS families are activated. 
Discussion
We have examined the mechanism of the pro-apoptotic action of the marine antitumor agent Aplidin s in human MDA-MB-231 breast cancer cells. Aplidin s rapidly induces cell death at doses in the nanomolar range. 4 This potent activity highlights the need to identify the precise action of the drug at the molecular level in order to search for target-directed screening methods, to improve its activity by rational modelling of the molecule, to analyze the activity of derivatives, and to design combined treatments with other antitumor drugs.
In this study we show that Aplidin s disrupts cellular glutathione homeostasis (GSSG/GSH ratio) by causing GSH depletion by several mechanisms including alteration of GPx and GR activity, and GSH extrusion to the medium. In addition, S-glutathiolation of proteins cannot be ruled out. Glutathione homeostasis is strictly regulated as a protection against oxidative stress. Aplidin s induces cellular oxidative stress as shown by the generation of ROS, which is reflected in the increase of lipids and DNA oxidation. Reactive oxygen species production is expected to deplete cellular antioxidant defenses, which enhances oxidative stress and cell injury. Our data indicate that Aplidin s induces GSH depletion, which in turn causes ROS production, as compounds that regulate GSH levels (Ebselen, N-acetylcystheine) inhibit Aplidin s action, while a range of general antioxidants do not.
Upon oxidative stress GSSG may exit from the cells, 28 but GSH extrusion through specific carriers is more important as an early step in the commitment of cells to apoptosis, being the cause rather than the consequence of oxidative stress by altering the reducing power of cells. 29, 30 Thus, human monocytic U937 and hepatoma HepG2 cells extrude GSH concomitantly to or before the development of apoptosis induced by puromycin or etoposide, a process that is ameliorated by methionine or cystathionine, inhibitors of the sinusoidal GSH transport system. 30 Likewise, apoptosis of Jurkat T lymphocytes caused by anti-Fas/Fas ligation induces a rapid efflux of GSH. 31 Our data using GSH transport inhibitors and direct measurement in the medium indicate that GSH extrusion is involved at least in late stages of Aplidin s action.
There is rapid exchange between mitochondrial and cytosolic GSH levels, and administration of GSH esters increases GSH levels in mitochondria more than those in the cytosol. 32 The finding that exogenously added GSH prevented the loss of mitochondrial membrane potential caused by Aplidin s strongly supports a critical role of GSH depletion in its cytotoxic action. Together, our results suggest that Previous data showed that sustained JNK activation is critical for Aplidin s -induced apoptosis. 10 Many regulators of JNK are known. 33 Among them, Rac acts upstream of kinase cascades that activate JNK via dual phosphorylation in threonine (Thr) and tyrosine (Tyr) residues within a Thr-ProTyr motif in the activation loop. 34 MKP-1 phosphatase inhibits JNK activity by dephosphorylation of these two residues. In addition, activated Rac induces ROS production through a direct effect on the mitochondria in rabbit synovial fibroblasts. 35 Our results reveal two rapid, gene expressionindependent mechanisms by which Aplidin s activates JNK: the combination of initial Rac1 activation and later MKP-1 downregulation is expected to lead to rapid, strong and sustained activation of JNK. The effect of Rac1, but not MKP-1, depends on GSH depletion. Our results showing that Rac1 downregulation by using siRNA reduces JNK activation and cytotoxicity by the drug indicate the importance of Rac1 activation for Aplidin s action. The reported finding that Rac1-deficient cells are not viable shows that a certain level of Rac1 is required for cell survival. This may explain the inability of Rac1 siRNA to completely abolish Rac1 expression and JNK activity in drug-treated cells. Further support for the crucial role of Rac1 in Aplidin s action derives from the reduction of drug-induced JNK activation and cytotoxicity. Taken together our data demonstrate that Aplidin s causes Rac1 activation leading to JNK activation and the induction of apoptosis in two different cell types.
The finding that MKP-1 deficient cells are only slightly more sensitive to the drug does not rule out a role of JNK in Aplidin s -induced cytotoxicity, since the activation of JNK in these cells is also slightly higher than in wild-type cells, probably due to compensatory mechanisms involving other phosphatases. Supporting a role of MKP-1 downregulation in apoptosis, it has been reported that MKP-1 stabilization by proteasome inhibitors is anti-apoptotic through the inhibition of JNK, 36 and chondrocyte death by tumor necrosis factor-a (TNF-a) is associated with sustained JNK activation, probably due to MKP-1 downregulation. 37 Presumably, MKP-1 downregulation potentiates JNK activation induced by Aplidin s via Rac1 activation (which is more evident at low doses) similarly to what happens in renal cancer cells, in which the MKP-1 expression inhibitor Ro-318220 enhances the pro-apoptotic effect of the JNK activator anisomycin. 38 There are many phosphatases acting on JNK; 34 however, MKP1 and MKP2 appear relevant as they are overexpressed in human breast cancer, and thus responsible for reduced JNK activity. 39 MKPs may thus be viable targets for therapeutic intervention to enable expression of the pro-apoptotic activity of JNK in breast cancer, 39 and Aplidin s may thus be a valuable therapeutic tool.
The mechanism of Aplidin s -induced apoptosis resembles several pathological cell death processes. One of them is the toxic effect of the combination of high homocysteine levels and Cu 2 þ . This combination decreases the GSH content, triggers the generation of ROS and induces loss of mitochondrial membrane potential and caspase-dependent apoptosis in vascular cells. 40 These data indicate similarities between Aplidin s and homocysteine/Cu 2 þ in the control of cellular GSH content. Additionally, the mechanism of action of Aplidin s is similar, but not identical to that of glutamate in neurons. Exogenous glutamate inhibits cystine uptake through the cystine/glutamate antiporter leading to GSH depletion, lipoxygenase activation, ROS production, opening of cGMP-gated channels and influx of extracellular Ca 2 þ , a form of cell death with characteristics of apoptosis and necrosis known as oxytosis. 41 In contrast to Aplidin s , this process is inhibited by protein kinase C activation, and involves damage of mitochondria and other organules but not DNA fragmentation. Glutamate toxicity in the mouse HT22 neuronal cell line causes two waves of ROS, an early one linked to GSH depletion, followed by a greater wave dependent on the influx of extracellular Ca 2 þ . 42 Together, these studies show that multiple agents can induce GSH depletion via different mechanisms (extrusion, inhibition of glutathione peroxidase, cystine antiporter, g-glutamylcysteine synthetase or g-glutamyl transpeptidase), and that GSH depletion can trigger distinct pathways leading to different forms of cell death depending on the strength of the stimulus and cellular ATP content.
Our results show that Aplidin s has a complex mechanism of cytotoxicity, which has similarities but also differences with other physiological and pathological cell death processes. The induction of GSH depletion is pivotal for downstream events of apoptosis: it triggers Rac1 activation, which together with MKP-1 downregulation leads to sustained JNK activation and cell death. Ongoing efforts seek to identify the primary cellular target(s) of Aplidin s responsible for the disruption of GSH homeostasis and Rac1 activation, and of MKP-1 downregulation. The strong pro-apoptotic activity and promising clinical data of Aplidin s emphasize the interest of this study.
Materials and Methods
Cell lines, antibodies, and reagents Antibodies used were anti-JNK1 and anti-MKP1 were from Santa Cruz; anti-phospho-JNK1 from New England Biolabs/Cell Signaling; antiGSTp1p2 from Calbiochem; anti-HA from Babco; anti-phosphotyrosine and anti-Rac1 monoclonal antibodies were from Transduction Laboratories/BD Biosciences (Heidelberg, Germany). 
Preparation of mouse embryonic fibroblasts
The primary wild-type and MKP-1-deficient (mkp-1
) MEF were isolated from 15 to 16-day-old embryos. Head and internal organs of the embryos were removed on a Petri plate with PBS and the trunk was dissected in 10 ml DMEM supplemented with 0.05% trypsin (Invitrogen) with fine scissors. After incubation at 371C for 10 min, the solution was pipetted up and down five times with a 20 ml glass pipette. This was repeated with 10 ml and 5 ml glass pipettes with 10 min incubation at 371C in between. Once complete, trypsinization was terminated by adding 5 ml fetal calf serum (FCS). Cell suspension and clumps were transferred into a Falcon tube and incubated for 2 min at 41C to sediment the clumps. Approximately 10 ml of the supernatant was transferred into a new tube through a 70 mm cell strainer (Falcon) leaving clumps behind. After centrifugation at 2000 r.p.m. for 5 min at room temperature, the pellet was washed once in 10 ml complete medium (DMEM supplemented with 10% FCS and 100 U/ml penicillin, 100 mg/ml streptomycin; Invitrogen). Cells were counted and plated up to 10 Â 10 6 cells per 15 cm plate. The next day, the medium was changed and the cells were cultured until they reached confluence. The cells were subcultured at a density of 5-10 Â 10 6 cells per 15 cm plate every 3 days. This process was repeated until they reached crisis and became established cell lines.
Flow cytometry analyses
Apoptotic cells were determined by their hypochromic, subdiploid staining profiles (subG1 population). Cells treated or not with Aplidin s were stained with PI and analyzed by flow cytometry (FACScan, Becton Dickinson, San Jose, CA, USA, equipped with a 488 nm argon ion laser). For staining, one million cells were harvested, washed in PBS and then fixed with 70% ethanol. Fixed cells were treated with DNAse-free RNAse for 30 min at 371C, washed in PBS, centrifuged, and incubated in PBScontaining PI (25 mg/ml; Sigma). Forward light scatter characteristics were used to exclude the cell debris from the analysis. Ten thousand events per sample were acquired for data analysis using CELLQUEST software by selective gating to exclude doublet cells. The results of the DNA content were modeled using ModFit (VERITY Software House, Inc., Topsham, ME). In RNA interference studies, FITC-annexin V and PI staining were analyzed: non-apoptotic living cells were FITC-annexin-V negative/PI negative, early apoptotic cells were FITC-annexin-V positive/PI negative, and late apoptotic cells were FITC-annexin-V positive/PI positive, whereas necrotic cells were FITC-annexin-V negative/low-PI positive.
To measure mitochondrial membrane potential (DCm), mitochondria were selectively probed with potential-sensitive JC-1 (5, 5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzimidazolylcarbocyanine iodide) (Molecular Probes). JC-1 was stocked as 1 mg/ml in DMSO and freshly diluted with complete culture medium. After treatments cells were harvested and incubated with medium containing JC-1 (10 mg/ml) for 10 min. Finally, cells were washed and resuspended in 1 ml PBS for flow cytometry analysis. JC-1 exhibits DCm-dependent accumulation in mitochondria, indicated by a shift in its fluorescence emission from green to red due to the formation of J-aggregates. Mitochondrial depolarization is thus indicated by a decrease in the red/green fluorescence ratio.
To analyze ROS, cells were stained with 2 0 ,7 0 -dichlorofluorescein diacetate (2 0 ,7 0 -DCFH-DA) (Molecular Probes). After incubation, the cells were trypsinized, washed in cold PBS and incubated for 30 min at 371C in medium containing 2 mM 2 0 ,7 0 -DCFH-DA and 5 mg/ml PI. To ensure that only living cells were analyzed, those that incorporated PI were excluded. The fluorescence intensity of intracellular 2 0 ,7 0 -DCFH-DA was determined in living cells by the CELLQUEST software.
Intracellular Ca 2 þ levels were estimated by labeling the cells with 1 mM Fluo-4 (Molecular Probes). Plasma membrane permeability was measured by labeling cells with 1 mg/ml Fluorescein diacetate (FDA; Molecular Probes) and 5 mg/ml PI for 30 min at 371C in normal growth medium.
Immunoprecipitation and Western-blot analysis
To study the effect of Aplidin s on the activity of JNK cells were preincubated for 24 h in serum-free medium. For immunoprecipitation cells were lysed in modified RIPA buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1% Triton X-100, 1% deoxycholic acid, 0.1% SDS, 1 mM Na3VO4, 25 mM b-glycerolphosphate, 100 mM NaF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF). Lysates were precleared by incubation with protein G-Sepharose at 41C for 30 min and then incubated overnight with the corresponding antibody (1 mg/ml). After 1 h incubation with protein G-sepharose, immune complexes were washed three times in the same RIPA buffer lacking deoxycholic acid and SDS and then three times with HNTG (50 mM Hepes pH 7.4, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 1 mM Na3VO4, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF) and electrophoresed in 10% acrylamide gels. For Western-blot analysis cell protein extracts were prepared as described. 4 Protein extracts were electrophoresed in 8 or 12% polyacrylamide gels and transferred to nitrocellulose (Immobilon P, Millipore) membranes. The filters were washed, blocked with 5% BSA in Tris-buffered saline (TBS) (25 mM Tris pH 7.4, 136 mM NaCl, 2.6 mM KCl, 0.5% Tween-20), and incubated overnight at 41C with the appropriate antibody. Blots were washed three times for 10 min in PBS þ 0.1% Tween-20 and incubated with HRP-or alkaline phosphatase-conjugated secondary antibodies for 1 h at room temperature. Blots were developed by a peroxidase reaction using the ECL detection system (G.E. Health Care) or the BCIP/NBT reaction and a colorimetric assay. thioredoxin (donated by Dr. J Yodoi, Kyoto) and the pSG5 vector as carrier to adjust the total amount of DNA. After overnight incubation with Lipofectamine-DNA mixtures, transfected cells were washed twice in PBS and incubated with fresh medium supplemented with 0.5% FCS. Each treatment was carried out in triplicate cultures. Protein extracts were prepared following standard procedures and analyzed by Western blotting. 4 Determination of oxidative stress-related parameters Lipid peroxidation assays: Malondialdehyde (MDA) was measured by Highpressure liquid chromatography (HPLC) as described. 44 DNA oxidation measurement: cell DNA was isolated and digested as described. 45 Levels of 8-oxo-2 0 -deoxyguanosine (8-oxo-dG) were measured by HPLC (Waters ODS HPLC column) followed by electrochemical and ultraviolet absorbance detection as described. 45 Cellular content of GSH and GSSG were measured by HPLC as previously described. 46, 47 Determination of GSH in the extracellular medium
The content of GSH was quantified by the fluorometric assay of Hissin and Hilf. 48 The method takes advantage of the reaction of reduced glutathione with o-phthalaldehyde (OPT) at pH 8.0. Conditioned culture medium was centrifuged to eliminate cells and debris and 50 ml was placed in a 96-well multiwell plus15 ml of 1 M NaOH and 175 ml of 0.1 M sodium phosphate buffer pH 8.0, containing 5 mM EDTA. Finally, 10 ml per well of a stock solution of OPT (10 mg/ml) in methanol was added and after 15 min at room temperature in the dark, fluorescence was measured at an emission wavelength of 460 nm and an excitation wavelength of 340 nm. The results of the samples were referred to those of a standard curve of GSH (5 ng -1 mg).
Measurement of glutathione peroxidase (GPx) and reductase (GR) activity
The activity of these two enzymes in extracts from cells treated or not with Aplidin s was measured using commercial kits following the manufacturer's recommendations (Cayman). 
Cell survival -MTT assays
Rac1 activity assays
Bacterial expression of fusion proteins. The plasmid pGEX-PAK-CRIB containing the Rac1-binding domain fused to GST was kindly provided by JG Collard (The Netherlands Cancer Institute). GST-fusion protein was purified (from Escherichia coli BL21 (DE3) harboring these plasmids) following the method previously described. 49 For in vitro binding assays, mammalian cells were lysed in cold lysis buffer and nucleus-free supernatants were incubated with the GST-fusion protein on glutathioneSepharose beads and analyzed as previously described. 49 
RNA interference
siRNA duplexes specific for Rac1 (Rac1.1, bases 529-550; Rac1.3, bases 605-626) were designed as described. 50 The siRNA sequence sense strand used as negative control for siRNA activity was AUUGUAUGC GAUCGCAGACdTdT. Control and Rac1 siRNA duplexes were purchased from Ambion (Austin, TX, USA). In addition, we also used the SMARTpool s siRNA reagent M-003560-02-0020 for human RAC1 (D-Mix) purchased from Dharmacon. siRNA duplexes (40 nM) were transfected using X-tremeGENE siRNA transfection reagent (Roche) and transfectants assayed 24 h post-transfection. Transfections did not affect cell viability.
To analyze the effect of Rac1 siRNA by flow cytometry cells were co-transfected with Rac1.1 or Control siRNA (40 nM) and 5 0 -carboxyfluorescein (FAM)-labeled unrelated negative control siRNA (4 nM). In addition, parallel cultures were transfected with b-actin siRNA instead of Rac1.1. All these siRNA oligonucleotides were from Ambion.
